SCHEMBL550449

SCHEMBL550449

Clc1ccc2[nH]c3cc4c(cc3c2c1)[nH]c1ccc(Cl)cc14

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHUK O15111 1/20 0.60
LMNA P02545 1/20 0.53
AHR P35869 1/20 0.52
HPGD P15428 2/20 0.52
CYP1A2 P05177 1/20 0.52
GAA P10253 1/20 0.52
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
PTGS2 P35354 2/20 0.51
ABCC4 O15439 1/20 0.51
C5 P01031 1/20 0.51
MAPT P10636 1/20 0.51
PTGS1 P23219 1/20 0.51
PDE4D Q08499 1/20 0.51
PARP1 P09874 1/20 0.50
CA12 O43570 1/20 0.48
CA9 Q16790 1/20 0.48
RXFP1 Q9HBX9 2/20 0.47
ALDH1A1 P00352 2/20 0.46
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29453525 0.95 CHUK (0.64) CHUKLMNAHPGDCYP1A2GAA
SCHEMBL607827 0.95 CHUK (0.64) CHUKLMNAHPGDCYP1A2GAA
SCHEMBL29354683 0.87 LMNA (0.56) CHUKLMNAHPGDCYP1A2GAA
SCHEMBL29586622 0.87 LMNA (0.56) CHUKLMNAHPGDCYP1A2GAA
SCHEMBL276018 0.87 LMNA (0.56) CHUKLMNAHPGDCYP1A2GAA
SCHEMBL2141394 0.85 PARP1 (0.61) CHUKLMNAAHRHPGDMEN1
SCHEMBL29643218 0.84 AHR (0.64) CHUKLMNAAHRHPGDMEN1
SCHEMBL29993295 0.84 AHR (0.64) CHUKLMNAAHRHPGDMEN1
SCHEMBL607394 0.84 AHR (0.64) CHUKLMNAAHRHPGDMEN1
SCHEMBL21448352 0.83 MEN1 (0.51) CHUKLMNAAHRHPGDCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140088313-A1 SUBSTITUTED INDOLOCARBAZOLES XEROX CORPORATION (US) 2014-03-27 US disclosed
US-8609867-B2 Substituted indolocarbazoles XEROX CORPORATION (US) 2013-12-17 US disclosed
US-20120157689-A1 SUBSTITUTED INDOLOCARBAZOLES XEROX CORPORATION (US) 2012-06-21 US disclosed
US-8110690-B2 Substituted indolocarbazoles XEROX CORPORATION (US) 2012-02-07 US disclosed
US-20090036689-A1 SUBSTITUTED INDOLOCARBAZOLES XEROX CORPORATION (US) 2009-02-05 US disclosed
US-7456424-B2 Thin film transistors including indolocarbozoles XEROX CORPORATION (US) 2008-11-25 US disclosed
US-20060124923-A1 Thin film transistors including indolocarbazoles XEROX CORPORATION 2006-06-15 US disclosed
US-20060125009-A1 Thin film transistors including indolocarbazoles XEROX CORPORATION 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036689-A1 SUBSTITUTED INDOLOCARBAZOLES HTR3C, HTR3A, AANAT CHUK 1758/4885LMNA 3353/4885AHR 41/4885
US-20120157689-A1 SUBSTITUTED INDOLOCARBAZOLES HTR3C, HTR3A, AANAT CHUK 1758/4885LMNA 3353/4885AHR 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.